Acknowledgements We thank Dr. Chad C. Bjorklund for assistance with mouse experiments, Dr. Joya Chandra for help with the mitochondrial membrane permeability measurements,
Dr. Jagannadha K. Sastry for his peptide expertise and help with preparation of this manuscript, Mrs. Angelique Harkins and Mrs. Frances Dressman for proofreading the manuscript. This work was supported by grants from the American Cancer Society (118447-MRSG-10-052-01-LIB to ZB), the National Institutes of Health (CA1206173, CA153170, CA158692, and DK091490 to F.S.), and the Leukemia CFTRinh-172 & Lymphoma Society (R6132-06 and R6187-09 to F.S.). We also thank the Richard Spencer Lewis Foundation, patients and their families for their support and willingness to join us in our efforts in developing new therapies for lymphoma. Electronic supplementary material Additional file 1 : Methods. www.selleckchem.com/products/idasanutlin-rg-7388.html (PDF 217 KB) References 1. Mahmood Z, Shukla Y: Death receptors: targets for cancer therapy. Exp Cell Res 2010, 316:887–899.PubMedCrossRef 2. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996,
2:574–577.PubMedCrossRef 3. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997, 99:403–413.PubMedCrossRef 4. de Totero D, Montera M, Rosso O, Clavio M, Balleari E, Foa R, Gobbi M: Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J 2004, 5:152–160.PubMedCrossRef 5. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B: Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005, 24:8114–8127.PubMed 6. Lajmanovich A, Irisarri M, Molens JP, Pasquier MA, Sotto JJ, Bensa
JC, Leroux D, Plumas J: Impairment of death-inducing signalling BAY 63-2521 in vitro complex formation in CD95-resistant human primary lymphoma B cells. Br J Haematol 2004, 124:746–753.PubMedCrossRef 7. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Dichloromethane dehalogenase Bensa JC: Tumor B cells from non-Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998, 91:2875–2885.PubMed 8. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F: Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl Cancer Inst 2009, 101:399–411.PubMedCrossRef 9. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U: A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 2006, 13:465–477.PubMedCrossRef 10.